501-3292
Production Way, Burnaby, B.C., V5A 4R4
info@cannabixtechnologies.com
cannabixtechnologies.com
Cannabix
Technologies Ramps Up Beta Testing with THC Breathalyzer and Ships
Additional Devices
Cannabix is
developing Marijuana Breathalyzer devices to give law enforcement
and employers a tool to enhance public safety
Vancouver, British Columbia --
September 27, 2021 -- InvestorsHub NewsWire -- Cannabix
Technologies Inc. (CSE: BLO) (OTC PINK: BLOZF) (the "Company" or "Cannabix")
developer of the Cannabix Marijuana Breathalyzer devices for law
enforcement and the workplace reports that it is ramping up subject beta
testing in a high-volume clinic in the Northwestern US and
will ship an
additional THC Breath Analyzer ("THCBA") unit to the site. The
collaborating clinic has a robust drug testing operation and is one
of the top drug testing providers to employers within its
respective state. The
Company also reports that it has shipped two THCBA devices to a
biomedical clinic in southern Ontario for beta-testing.
The THCBA is a drug screening
device for employers and other markets who are seeking a way to
quickly (in less than 5 minutes), easily and non-invasively test
for recent use of ?9-tetrahydrocannabinol ("THC") - the
psychoactive component of marijuana that causes impairment. The
THCBA consists of a handheld device and protective case which
houses a sterilization module, sample preparation stage, device
recovery station and integrated battery charging system. Over the
course of 2020 to present the Company has been relentlessly focused
on building the THCBA from bench prototypes to the current
hand-held portable version 3.0 system. Over recent months, this
proof-of-concept system has been introduced into small scale
beta-testing sites. The
focus of the beta-testing has been to gather information on user
and administrator experience, identifying cross-reactivity of other
substances within a semi-controlled study population and to further
collect data and train the device's machine learning database and
sensitivity profile. Furthermore, feedback has been provided in
areas of handling, connectivity, operating procedures and data
management.
While beta-testing the version 3.0,
company engineers have begun building a THCBA version 4.0 that
incorporates feedback from beta-test sites and strategic design
changes. The version 4.0 design changes will be geared towards
manufacturability and reproducibility, while improving device
performance. Several components such as the device's internal
sampling chambers are being optimized for production. The
microfluidic sensor and related actuator mechanism design have been
simplified to minimize manufacturing variability and reduce cost.
Several other components have been upgraded to more robust
materials that will reduce assembly constraints and simplify
tooling.
Company engineers have been
planning these upgrades and changes since Q1 and are well into the
design of the version 4.0 device which is targeted for
pre-production small batch runs in Q4 (2021) followed by broad
field testing and clinical testing to establish V4.0 benchmark
standards.
The Company also reports that it
has begun preliminary discussions with potential manufacturers in
North America for the THCBA.
About Cannabix Technologies
Inc.
Cannabix Technologies Inc. is a
developer of marijuana breathalyzer technologies for law
enforcement and the workplace. Cannabix is working to develop
drug-screening devices that will detect THC - the psychoactive
component of marijuana that causes impairment using breath samples.
Breath testing for THC would allow employers and law enforcement
to identify recent marijuana use that
better aligns with impairment. Cannabix devices are in the advanced
prototype and pre-clinical testing stage.
We seek Safe
Harbor.
On behalf of the
Board of Directors
"Rav Mlait"
CEO
Cannabix Technologies
Inc.
For further information, contact
the Company at
info@cannabixtechnologies.com
The CSE has not
reviewed and does not accept responsibility for the adequacy or
accuracy of this release.
Cautionary Statement
Regarding Forward-Looking Statements
This press release
contains forward-looking information that involves various risks
and uncertainties regarding future events. Such forward-looking
information can include without limitation statements based on
current expectations involving a number of risks and uncertainties
and are not guarantees of future performance of the Company, such
as final development of a commercial or prototype product(s),
successful trial or pilot of company technologies, no assurance
that commercial sales of any kind actually materialize; no
assurance the Company will have sufficient funds to complete
product development. There are numerous risks and uncertainties
that could cause actual results and the Company's plans and
objectives to differ materially from those expressed in the
forward-looking information, including: (i) adverse market
conditions; (ii) risks regarding protection of proprietary
technology; (iii) the ability of the Company to complete
financings; (iv) the ability of the Company to develop and market
its future product; and (v) risks regarding government regulation,
managing and maintaining growth, the effect of adverse publicity,
litigation, competition and other factors which may be identified
from time to time in the Company's public announcements and
filings. There is no assurance that its development of marijuana
breathalyzer technology will provide any benefit to the Company,
and no assurance that any proposed new products will be built, will
be successful in beta testing or clinical trials. There is no
assurance that existing "patent pending" technologies licensed by
the Company will receive patent status by regulatory
authorities.
The Company is not
currently selling commercial breathalyzers. Actual results and
future events could differ materially from those anticipated in
such information. These and all subsequent written and oral
forward-looking information are based on estimates and opinions of
management on the dates they are made and are expressly qualified
in their entirety by this notice. Except as required by law, the
Company does not intend to update these forward-looking
statements.